BioMarin Pharmaceutical (BMRN) return on equity (ROE)

Return on equity · fiscal 2025
5.7%

BioMarin Pharmaceutical (BMRN) earned a return on equity of 5.7% in fiscal 2025 (the year ended December 31, 2025). That is 1.8 percentage points lower than the 7.5% of fiscal 2024. Figures as of 17 Nov 2026, 23:43 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2025
5.7%
Change on fiscal 2024
−1.8 pts
Highest on record
28.7%fiscal 2010
Lowest on record
-22.8%fiscal 2016
Fiscal years on record
182008–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

BioMarin Pharmaceutical return on equity (ROE), in more detail

Across the 18 fiscal years on record (2008–2025), the highest was 28.7% in fiscal 2010 and the lowest -22.8% in fiscal 2016. The fiscal 2025 figure is higher than in 76% of the 17 earlier fiscal years on record, whose median is -1.5%.

History · 18 fiscal years

Return on equity by fiscal year

BioMarin Pharmaceutical return on equity (ROE), year by year

BioMarin Pharmaceutical (BMRN) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
20255.7% 1.8 pts down
20247.5% 4.2 pts up
20233.4% 0.3 pts up
20223.1% 4.6 pts up
2021-1.5% 22.3 pts down
202020.8% 21.6 pts up
2019-0.8% 1.8 pts up
2018-2.6% 1.6 pts up
2017-4.2% 18.6 pts up
2016-22.8% 15.6 pts down
2015-7.2% 1.6 pts up
2014-8.8% 4.4 pts up
2013-13.2% 1.9 pts down
2012-11.3% 4.3 pts down
2011-7.0% 35.7 pts down
201028.7% 28.8 pts up
2009-0.2% 11.3 pts down
200811.1%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

Return on equity at health care companies of similar size

Return on equity of BioMarin Pharmaceutical and comparable companies
CompanyReturn on equityFiscal year
Universal Health Services UHS20.5%2025
Repligen RGEN2.3%2025
Bio-Techne TECH8.6%2026
BioMarin Pharmaceutical BMRN5.7%2025
Avantor AVTR-9.5%2025
Ensign Group ENSG15.4%2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on BMRN

BioMarin Pharmaceutical, figure by figure

BioMarin Pharmaceutical (BMRN) overview: price, valuation and scorecardAll health care companies by market value

BioMarin Pharmaceutical return on equity (ROE): questions and answers

What is BioMarin Pharmaceutical's return on equity?

BioMarin Pharmaceutical (BMRN) earned a return on equity of 5.7% in fiscal 2025 (the year ended December 31, 2025). That is 1.8 percentage points lower than the 7.5% of fiscal 2024.

Is BioMarin Pharmaceutical's return on equity high or low compared with its own history?

The fiscal 2025 figure is higher than in 76% of the 17 earlier fiscal years on record, whose median is -1.5%.

What are the highest and lowest return on equity figures on record for BioMarin Pharmaceutical?

Across the 18 fiscal years on record (2008–2025), the highest was 28.7% in fiscal 2010 and the lowest -22.8% in fiscal 2016.

How is BioMarin Pharmaceutical's return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “BioMarin Pharmaceutical (BMRN) return on equity (ROE)”, data as of 17 November 2026. https://funkfolio.com/stock/BMRN/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.